Logo image of STRO

SUTRO BIOPHARMA INC (STRO) Stock Fundamental Analysis

USA - NASDAQ:STRO - US8693671021 - Common Stock

1.05 USD
-0.01 (-0.94%)
Last: 10/24/2025, 8:00:00 PM
1.07 USD
+0.02 (+1.9%)
After Hours: 10/24/2025, 8:00:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to STRO. STRO was compared to 534 industry peers in the Biotechnology industry. STRO may be in some trouble as it scores bad on both profitability and health. STRO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year STRO has reported negative net income.
STRO had a negative operating cash flow in the past year.
STRO had negative earnings in each of the past 5 years.
In the past 5 years STRO reported 4 times negative operating cash flow.
STRO Yearly Net Income VS EBIT VS OCF VS FCFSTRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of STRO (-79.55%) is worse than 68.35% of its industry peers.
Industry RankSector Rank
ROA -79.55%
ROE N/A
ROIC N/A
ROA(3y)-36.91%
ROA(5y)-29.96%
ROE(3y)-212.09%
ROE(5y)-137.55%
ROIC(3y)N/A
ROIC(5y)N/A
STRO Yearly ROA, ROE, ROICSTRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

STRO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STRO Yearly Profit, Operating, Gross MarginsSTRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

STRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for STRO has been increased compared to 1 year ago.
The number of shares outstanding for STRO has been increased compared to 5 years ago.
There is no outstanding debt for STRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
STRO Yearly Shares OutstandingSTRO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
STRO Yearly Total Debt VS Total AssetsSTRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

STRO has an Altman-Z score of -5.45. This is a bad value and indicates that STRO is not financially healthy and even has some risk of bankruptcy.
STRO has a Altman-Z score of -5.45. This is in the lower half of the industry: STRO underperforms 63.48% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.45
ROIC/WACCN/A
WACC9.51%
STRO Yearly LT Debt VS Equity VS FCFSTRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 3.12 indicates that STRO has no problem at all paying its short term obligations.
With a Current ratio value of 3.12, STRO is not doing good in the industry: 63.11% of the companies in the same industry are doing better.
STRO has a Quick Ratio of 3.12. This indicates that STRO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of STRO (3.12) is worse than 60.11% of its industry peers.
Industry RankSector Rank
Current Ratio 3.12
Quick Ratio 3.12
STRO Yearly Current Assets VS Current LiabilitesSTRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

2

3. Growth

3.1 Past

STRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.25%.
STRO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -38.31%.
STRO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.74% yearly.
EPS 1Y (TTM)-38.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.27%
Revenue 1Y (TTM)-38.31%
Revenue growth 3Y0.09%
Revenue growth 5Y7.74%
Sales Q2Q%147.98%

3.2 Future

Based on estimates for the next years, STRO will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.52% on average per year.
The Revenue is expected to grow by 0.95% on average over the next years.
EPS Next Y34.69%
EPS Next 2Y26.05%
EPS Next 3Y17.01%
EPS Next 5Y14.52%
Revenue Next Year70.59%
Revenue Next 2Y-3.62%
Revenue Next 3Y-4.71%
Revenue Next 5Y0.95%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
STRO Yearly Revenue VS EstimatesSTRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
STRO Yearly EPS VS EstimatesSTRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

STRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STRO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STRO Price Earnings VS Forward Price EarningsSTRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STRO Per share dataSTRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

STRO's earnings are expected to grow with 17.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.05%
EPS Next 3Y17.01%

More info and screens

0

5. Dividend

5.1 Amount

STRO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SUTRO BIOPHARMA INC

NASDAQ:STRO (10/24/2025, 8:00:00 PM)

After market: 1.07 +0.02 (+1.9%)

1.05

-0.01 (-0.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners62.76%
Inst Owner Change-0.05%
Ins Owners0.72%
Ins Owner Change4.26%
Market Cap89.01M
Revenue(TTM)104.47M
Net Income(TTM)-208697000
Analysts75
Price Target2.74 (160.95%)
Short Float %3.07%
Short Ratio2.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)19.89%
Min EPS beat(2)-26.1%
Max EPS beat(2)65.88%
EPS beat(4)2
Avg EPS beat(4)14.02%
Min EPS beat(4)-26.1%
Max EPS beat(4)65.88%
EPS beat(8)4
Avg EPS beat(8)29.5%
EPS beat(12)6
Avg EPS beat(12)24.27%
EPS beat(16)6
Avg EPS beat(16)15.42%
Revenue beat(2)2
Avg Revenue beat(2)192.69%
Min Revenue beat(2)46.91%
Max Revenue beat(2)338.47%
Revenue beat(4)3
Avg Revenue beat(4)89.22%
Min Revenue beat(4)-45.24%
Max Revenue beat(4)338.47%
Revenue beat(8)7
Avg Revenue beat(8)156.79%
Revenue beat(12)9
Avg Revenue beat(12)108.33%
Revenue beat(16)10
Avg Revenue beat(16)81.97%
PT rev (1m)0%
PT rev (3m)-17.54%
EPS NQ rev (1m)1.06%
EPS NQ rev (3m)-26.57%
EPS NY rev (1m)0%
EPS NY rev (3m)1.56%
Revenue NQ rev (1m)0.43%
Revenue NQ rev (3m)-33.22%
Revenue NY rev (1m)0%
Revenue NY rev (3m)71.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.85
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.53
EYN/A
EPS(NY)-1.24
Fwd EYN/A
FCF(TTM)-2.97
FCFYN/A
OCF(TTM)-2.94
OCFYN/A
SpS1.23
BVpS-0.38
TBVpS-0.38
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.55%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.91%
ROA(5y)-29.96%
ROE(3y)-212.09%
ROE(5y)-137.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.27%
Cap/Sales 3.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.12
Quick Ratio 3.12
Altman-Z -5.45
F-Score2
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)81.45%
Cap/Depr(5y)145.34%
Cap/Sales(3y)6.47%
Cap/Sales(5y)12.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.27%
EPS Next Y34.69%
EPS Next 2Y26.05%
EPS Next 3Y17.01%
EPS Next 5Y14.52%
Revenue 1Y (TTM)-38.31%
Revenue growth 3Y0.09%
Revenue growth 5Y7.74%
Sales Q2Q%147.98%
Revenue Next Year70.59%
Revenue Next 2Y-3.62%
Revenue Next 3Y-4.71%
Revenue Next 5Y0.95%
EBIT growth 1Y-56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year56.15%
EBIT Next 3Y16.25%
EBIT Next 5YN/A
FCF growth 1Y-343.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-395.74%
OCF growth 3YN/A
OCF growth 5YN/A

SUTRO BIOPHARMA INC / STRO FAQ

What is the ChartMill fundamental rating of SUTRO BIOPHARMA INC (STRO) stock?

ChartMill assigns a fundamental rating of 1 / 10 to STRO.


What is the valuation status of SUTRO BIOPHARMA INC (STRO) stock?

ChartMill assigns a valuation rating of 0 / 10 to SUTRO BIOPHARMA INC (STRO). This can be considered as Overvalued.


Can you provide the profitability details for SUTRO BIOPHARMA INC?

SUTRO BIOPHARMA INC (STRO) has a profitability rating of 0 / 10.


What is the financial health of SUTRO BIOPHARMA INC (STRO) stock?

The financial health rating of SUTRO BIOPHARMA INC (STRO) is 2 / 10.


Can you provide the expected EPS growth for STRO stock?

The Earnings per Share (EPS) of SUTRO BIOPHARMA INC (STRO) is expected to grow by 34.69% in the next year.